Neuroplasticity of excitatory and inhibitory cortical circuits in schizophrenia by Lewis, David A.
europlasticity can be broadly considered to be
the capacity of the brain to change the molecular and
structural features that dictate its functions in response
to a disease process (or other factors) that disrupts those
functions.
1 For a disorder such as schizophrenia, the dis-
ease process appears to result from a complex interplay
of an unknown number of genetic liabilities and envi-
ronmental risk factors that unleash pathogenetic mech-
anisms which produce a pathological entity, a conserved
set of molecular and cellular disturbances in specific
neural circuits. These pathological changes so alter the
normal function of the affected circuits that the result-
ing pathophysiology gives rise to the emergent proper-
ties recognized as the clinical features of the illness.
2 One
approach to dissecting this disease process involves
focusing on a well-defined clinical component of the ill-
ness. For example, deficits in cognitive abilities are
thought to be the core features of schizophrenia because
they occur with high frequency in individuals with schiz-
ophrenia, are relatively stable over the course of the ill-
ness, are independent of the psychotic symptoms of the
disorder, are present in a milder form in individuals at
genetic risk who do not become clinically ill,
3 and are the
best predictor of long-term functional outcome.
4
Of the domains of cognition affected in schizophrenia,
disturbances in working memory, the ability to tran-
siently maintain and manipulate a limited amount of
information in order to guide thought or behavior, are
accompanied by altered activation of the dorsolateral
prefrontal cortex (DLPFC, Figure 1 A, B). The altered
activation of the DLPFC under such conditions might be
specific to the disease process of schizophrenia because
these disturbances are present in medication-naïve indi-
viduals with schizophrenia, but not in subjects with other
psychotic disorders or major depression.
5,6
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Schizophrenia is a neurodevelopmental disorder charac-
terized by deficits in cognitive processes mediated by the
circuitry of the dorsolateral prefrontal cortex (DLPFC).
These deficits are associated with a range of alterations in
DLPFC circuitry, some of which reflect the pathology of the
illness and others of which reflect the neuroplasticity of the
brain in response to the underlying disease process. This
article reviews disturbances in excitatory and inhibitory
components of DLPFC circuitry from the perspective of
developmental neuroplasticity and discusses their implica-
tions for the identification of novel therapeutic targets.
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:269-280.
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tatory and inhibitory neurotransmission in DLPFC cir-
cuitry that might contribute to the impairments in work-
ing memory in schizophrenia. Each mediator is
considered from the perspective of which alterations
reflect the disease process and which might be neuro-
plastic responses of the affected circuits. Although addi-
tional studies are required, existing data suggests that
many of the alterations described below are probably
also present in other cortical regions that are dysfunc-
tional in schizophrenia.
7
Neuroplasticity of excitatory cortical 
connections in schizophrenia
Excitatory connections in the DLPFC are altered in
schizophrenia
The disease process of schizophrenia appears to involve
deficient glutamate-mediated excitatory neurotransmis-
sion through the N-methyl-D-aspartic acid (NMDA)
receptor.
8,9 NMDA receptor antagonists such as phency-
clidine (PCP) or ketamine increase both positive and
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Selected abbreviations and acronyms
CCK cholecystokinin
DLPFC dorsolateral prefrontal cortex
GABA γ-aminobutyric acid
GAD glutamic acid decarboxylase
GAT GABA membrane transporter
NMDA N-methyl-D-aspartic acid
PV parvalbumin
Figure 1. A) Photograph of an unstained coronal block, containing the prefrontal cortex, cut immediately anterior to the corpus callosum through
the left hemisphere of a postmortem human brain. This block also includes the adjacent anterior cingulate gyrus (ACG) of the limbic lobe.
The portion of the dorsolateral prefrontal cortex (DLFPC) delineated by the small rectangle is shown at higher magnification in panel B. B)
Nissl-stained section showing the typical appearance of six layers or lamina, numbered from the pial surface of the cortex to the underlying
white matter, based on the size and packing density of neurons. C) Schematic representation of neurons across cortical layers. Pyramidal neu-
rons (red) represent about 75% of cortical neurons and typically have triangularly-shaped cell bodies, a single apical dendrite directed towards
the pial surface, and an array of basilar dendrites. Depending on their laminar location, the axons of pyramidal neurons preferentially provide
excitatory projections to different brain regions. Axons that project to the DLPFC from other brain regions also tend to innervate different sub-
sets of cortical layers. For example, axonal projections (green) from the thalamus terminate in layers deep 3 and 4. The remaining ~25% of
DLPFC neurons are local circuit or interneurons (blue). These neurons use the inhibitory neurotransmitter GABA, and have axons that arborize
locally and innervate other neurons in the same area of the prefrontal cortex. 
Reproduced from ref 1: Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2008;33:141-165.
Copyright © Nature Publishing Group 2008
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the administration of subanesthetic doses of ketamine
to healthy individuals produces thought disorder and
other features similar to those seen in schizophrenia.
10
In addition, systemic administration of NMDA receptor
antagonists disrupts working memory in rats,
11 and appli-
cation of an NMDA receptor antagonist to the DLPFC
impairs working memory performance in monkeys.
12
However, although postmortem studies have reported
alterations in measures of glutamate receptor binding,
transcription, and subunit protein expression in several
brain regions in subjects with schizophrenia,
13 such find-
ings for mRNA and protein levels of NMDA receptor
subunits in the DLPFC have been limited in magnitude
and not always replicated, suggesting that other compo-
nents of NMDA receptor signaling might be affected in
the illness.
14
Anatomical studies do support the presence of input-
specific alterations of excitatory connections in the
DLPFC in schizophrenia. In the DLPFC, pyramidal neu-
rons (Figure 1C) are the principal source of glutamate
neurotransmission, as well as the targets of the majority
of glutamate-containing axon terminals. Although the
number of these neurons does not appear to be altered
in schizophrenia,
15,16 neuronal density in the DLPFC has
been reported to be increased in schizophrenia.
17
Increased cell packing density has been interpreted as
evidence of a reduction in the amount of cortical neu-
ropil, the axon terminals, dendritic spines, and glial
processes that occupy the space between neurons.
18
Consistent with this interpretation, synaptophysin pro-
tein, a marker of axon terminals, has been reported to
be decreased in the DLPFC of subjects with schizo-
phrenia.
19-21 Furthermore, gene expression profiling stud-
ies have found reduced tissue levels of gene transcripts
that encode proteins involved in the presynaptic regula-
tion of neurotransmission.
22
Dendritic spines are the principal targets of excitatory
synapses to pyramidal neurons. Although most dendritic
spines present are stable in number during adulthood,
23
they are subject to a number of neuroplastic changes,
such as a loss of their presynaptic excitatory input. In
schizophrenia, dendritic spine density in pyramidal neu-
rons has been reported to be lower in the DLPFC
24,25;
understanding the nature of these neuroplastic
responses requires knowledge of the specific circuits that
are affected and the developmental mechanisms that
might underlie these changes. 
Reduced excitatory connections in schizophrenia are
specific to a subset of pyramidal neurons
Pyramidal neurons can be divided into subgroups based
on the brain region targeted by their principal axonal
projection and the sources of their excitatory inputs;
both of these characteristics are associated with the
location of pyramidal cell bodies in different layers of
the cortex (Figure 1C). For example, many pyramidal
cells in layers 2 to 3 send axonal projections to other
cortical regions, pyramidal neurons in layer 5 tend to
project to the striatum and other subcortical structures,
and pyramidal neurons in layer 6 furnish projections
primarily to the thalamus.
26 Studies of basilar dendritic
spine density on Golgi-impregnated pyramidal neurons
in each cortical layer of the DLPFC in the same cohort
of subjects found a significant effect of diagnosis on
spine density only for pyramidal neurons in deep layer
3 (Figure 2).
25,27
The functional integrity of the pyramidal neurons with
lower dendritic spine densities may be reflected in
changes in their somal volume. For example, shifts in
somal size may indicate disturbances in neuronal con-
nectivity, given that somal size has been shown to be cor-
related with measures of a neuron's dendritic tree
28 and
axonal arbor.
29 Indeed, the mean cross-sectional somal
area of the Golgi-impregnated, deep layer 3 pyramidal
neurons was 9% smaller in the subjects with schizo-
phrenia relative to normal control subjects.
25 Consistent
with this observation, the mean somal volume of Nissl-
stained pyramidal neurons in DLPFC deep layer 3 was
also 9% smaller in a different cohort of subjects with
schizophrenia.
30 Similarly, in another study, the mean
somal size of all layer 3 neurons in DLPFC area 9 was
smaller in subjects with schizophrenia, and was accom-
panied by a decrease in the density of the largest neu-
rons in deep layer 3, without a change in somal volume
in layer 5.
31 Furthermore, in both primary and associa-
tion auditory cortices, somal volumes of deep layer 3, but
not of layer 5, pyramidal neurons were smaller in schiz-
ophrenia.
32,33 Together, these findings suggest that in
schizophrenia: i) basilar dendritic spine density is lower
and somal volume is smaller in deep layer 3 pyramidal
neurons; ii) these alterations are specific to or at least
most prominent in deep layer 3; iii) this pattern of alter-
ations is not restricted to the DLPFC; and iv) these dif-
ferences reflect the underlying disease process and not
confounding factors. 
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dendritic spine alterations in schizophrenia
Dendritic spine density on DLPFC layer 3 pyramidal
neurons undergoes a substantial decline during adoles-
cence in primates.
34 Consistent with the findings that
dendritic spines are the main site of excitatory synaptic
input onto pyramidal cells and that all mature dendritic
spines contain an excitatory synapse,
35 the number of
excitatory synapses declines in a similar age-related fash-
ion in both monkey and human DLPFC.
36,37 In humans,
this synaptic pruning is thought to underlie the decrease
in cortical gray matter thickness that occurs during ado-
lescence.
38,39 Interestingly, the late developmental refine-
ments in excitatory connectivity are more marked in
layer 3 than in the deeper cortical layers,
36 suggesting
that they may be associated with the apparent lamina-
specific alterations in spine density in schizophrenia. The
observation of alterations in the expression of certain
synaptic proteins in schizophrenia suggested the possi-
bility that the exuberant synapses present before ado-
lescence somehow compensated for a dysfunction in
excitatory transmission in individuals with schizophre-
nia.
40 Alternatively, such alterations in synaptic protein
expression might disturb the mechanisms of adoles-
cence-related synapse elimination leading, for instance,
to excessive synapse pruning and decreased spine num-
ber in the illness.
41,42
The potential contribution of excitatory synapse prun-
ing during adolescence to disease-related changes in
DLPFC function depends, in part, on the functional
properties of the synapses that are pruned. During early
brain development, pruned synapses are functionally
immature. Immature glutamate synapses are relatively
weak and their maturation involves an activity-depen-
dent increase in strength. Such activity-dependent
strengthening might underlie synapse stabilization, and
thus mark for elimination the immature synapses that
are not strengthened.
43,44 However, recent findings in the
developing monkey DLPFC indicate that the excitatory
inputs to layer 3 pyramidal neurons mature functionally
during the age range when they are present in high den-
sity and before synaptic pruning begins.
45 Thus, these
data suggest that the substantial remodeling of excita-
tory connectivity of the primate DLPFC during adoles-
cence primarily involves the elimination of mature
synapses, and that some other factor, such as the neu-
ronal source of input, somehow tags mature synapses for
pruning.
46 Thus, the presence of functionally mature
synapses prior to adolescence supports the hypothesis
that the excess in excitatory synapse number prior to
adolescence might be able to compensate for a molecu-
lar based dysfunction of these synapses in individuals
with schizophrenia, and thereby forestall the appearance
of the clinical features of the illness until synapse num-
ber falls below some critical threshold.
40
Neuroplasticity of inhibitory cortical 
connections in schizophrenia
Prefrontal inhibitory neurotransmission is altered in
schizophrenia
Studies from multiple laboratories have consistently found
lower levels of the mRNA for the 67 kilodalton isoform of
glutamic acid decarboxylase (GAD67), the principal syn-
thesizing enzyme for γ-aminobutyric acid (GABA), in the
DLPFC of subjects with schizophrenia.
16,22,47-52At the cellu-
lar level, the expression of GAD67 mRNA was not
detectable in ~25% to 35% of GABA neurons in layers 1-
5 of the DLPFC, but the remaining GABA neurons exhib-
ited normal levels of GAD67 mRNA.
16,47 Similarly, expres-
sion of the mRNA for the GABA membrane transporter
(GAT1), a protein responsible for reuptake of released
GABA into nerve terminals, was decreased in a similar
minority of GABA neurons.
53These findings suggest that
both the synthesis and reuptake of GABA are lower in a
subset of DLPFC neurons in schizophrenia. 
Subclasses of cortical GABA neurons can be distin-
guished on the basis of a number of molecular, electro-
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Figure 2. Pyramidal neuron dendritic spines in the human DLPFC. A) Schematic diagram illustrating the dendritic tree and dendritic spines on a proto-
typic pyramidal neuron. B) Electron micrograph showing a dendrite (D) with two spines (S). Each spine receives an asymmetric (presumably
excitatory) synapse from an axon terminal (at). C) Golgi-impregnated basilar dendrites and spines on deep layer 3 pyramidal neurons from a
normal comparison (top) and two subjects with schizophrenia (bottom). Note the reduced density of spines in the subjects with schizophre-
nia in these extreme examples. D) Scatter plot demonstrating the lower density of spines on the basilar dendrites of deep layer 3 pyramidal
neurons in the DLPFC of subjects with schizophrenia relative to both normal and psychiatrically-ill comparison subjects. E) Laminar-specificity
of the spine density differences in the same subjects. 
Reproduced from ref 1: Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2008;33:141-165.
Copyright © Nature Publishing Group 2008
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the affected GABA neurons in schizophrenia include
the subclass that contain the calcium-binding protein,
parvalbumin (PV), which comprise ~25% of GABA
neurons in the primate DLPFC. PV-containing neurons
include fast-spiking chandelier and basket neurons that
principally target the axon initial segments and cell
body/proximal dendrites, respectively, of pyramidal neu-
rons
54,55 (Figure 3). In individuals with schizophrenia the
expression level of PV mRNA is reduced, although the
number of PV neurons appears to be unchanged
56; in
addition, approximately half of PV mRNA-containing
neurons lack detectable levels of GAD67 mRNA.
57 In
contrast, the ~50% of GABA neurons that express the
calcium binding protein calretinin appear to be unaf-
fected.
57
In the DLPFC of subjects with schizophrenia, GAT1
immunoreactivity is selectively reduced in the charac-
teristic axon terminals (cartridges) of PV-containing
chandelier neurons.
58 In the postsynaptic targets of
these axon cartridges, the axon initial segments of
pyramidal neurons, immunoreactivity for the GABAA
receptor α2 subunit (which is present in most GABAA
receptors in this location
59) is markedly increased in
schizophrenia.
60 Several lines of evidence suggest that
the reductions in presynaptic GABA markers (GAT1
and PV) and increased postsynaptic GABAA recep-
tors are compensatory responses to a deficit in GABA
release from chandelier neurons. For example, PV is a
slow calcium buffer that does not affect the amplitude,
but accelerates the decay, of Ca
2+ transients in GABA
nerve terminals.
61,62 Thus, PV decreases the residual
Ca
2+ levels that normally accumulate in nerve termi-
nals and facilitate GABA release during repetitive fir-
ing.
61 Studies in PV-deficient mice have demonstrated
that a decrease in PV increases residual Ca
2+ and
favors synaptic facilitation.
61,63 Furthermore, the
enhanced facilitation of GABA release from fast-spik-
ing neurons with reductions in PV is associated with
increased power of gamma oscillations
63 (which is, as
explained below, deficient in schizophrenia). Similarly,
the blockade of GABA reuptake via GAT1 prolongs
the duration of inhibitory postsynaptic currents
(IPSCs) when synapses located close to each other are
activated synchronously
64; the resulting prolongation
of IPSCs increases the probability of IPSC summation,
enhances the total efficacy of IPSC trains, and thereby
augments GABA signaling. The upregulation of the
postsynaptic GABAA receptors that contain α2 sub-
units would be expected to increase the efficacy of the
GABA that is released from chandelier neurons. Thus,
the combined reduction of PV and GAT1 proteins in
chandelier cell axon cartridges, and the upregulation
of postsynaptic GABAA receptors, appear to represent
neuroplastic responses that might act synergistically to
increase the efficacy of GABA neurotransmission at
pyramidal neuron axon initial segments during the
types of repetitive neuronal activity associated with
working memory. 
However, the persistence of cognitive impairments in
individuals with schizophrenia suggests that these neu-
roplastic changes in GABA neurotransmission from
chandelier neurons are insufficient as compensatory
responses. Alternatively, it is possible that compensa-
tion at chandelier cell synapses is not effective because
additional interneuron subclasses are also functionally
deficient in schizophrenia.
65 Consistent with this inter-
pretation, other findings indicate that alterations in PV-
containing GABA neurons cannot account for all of
the observed findings in postmortem studies of schizo-
phrenia. For example, the levels of GAD67 and GAT1
mRNAs are reduced to comparable degrees in layers
2-5,
47,53 even though the density of PV neurons is much
greater in layers 3 and 4 than in layers 2 and 5.
66 In
addition, PV mRNA expression was reduced in layers
3 and 4, but not in layers 2 and 5, in subjects with schiz-
ophrenia.
57 Indeed, other studies have found lower tis-
sue concentrations of the mRNAs for the neuropep-
tides somatostatin (SST) and cholecystokinin (CCK) in
the DLPFC of subjects with schizophrenia (Figure 3).
51
In the cortex, SST is expressed by GABA neurons
located in layers 2 and 5 that do not express PV or
CR.
67 CCK is also heavily expressed in GABA neurons
that do not contain either PV or SST located princi-
pally in layers 2-3 of the primate prefrontal cortex.
68
Interestingly, the axon terminals of CCK-containing
large basket neurons, which target selectively pyrami-
dal neuron cell bodies, contain type I cannabinoid
receptors (CB1R),
69 and the mRNA and protein levels
of CB1R are also lower in schizophrenia.
70 Because
activation of the CB1R suppresses GABA release from
the terminals of CCK neurons, the downregulation of
this receptor may represent a compensatory response
to reduce the ability of endogenous cannabinoids to
decrease GABA release from CCK/CB1R-containing
axon terminals.
70
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Figure 3. Schematic summary of putative alterations in DLPFC circuitry in schizophrenia. Pyramidal neurons (light blue) in deep layer 3 have smaller
somal size, shorter basilar dendrites, lower dendritic spine density, and a reduced axonal arbor in schizophrenia. Altered GABA neurotrans-
mission by PV-containing neurons (green) is indicated by expression deficits in several gene products as well as by lower levels of GAT1 pro-
tein in the terminals of chandelier neurons and upregulated GABAA receptor α2 subunits at their synaptic targets, the axon initial segments
of pyramidal neurons (enlarged square). Expression of the neuropeptide somatostatin (SST) is decreased in GABA neurons (dark blue) that tar-
get the distal dendrites of pyramidal neurons. Decreased cholecystokinin (CCK) and cannabinoid receptor 1 (CB1) mRNA levels, and lower
CB1 protein in axon terminals, suggest altered regulation of GABA neurotransmission in a subset of basket neurons (purple) that target the
cell body and proximal dendrites of pyramidal neurons. Gene expression does not seem to be altered in calretinin (CR)-containing GABA neu-
rons (red) that primarily target other GABA neurons (gray). Putative alterations in thalamic and dopamine (DA) cell bodies and their projec-
tions to the DLPFC are also shown. Some studies indicate that the number and/or gene expression in oligodendrocytes is also altered. Not
all of the circuitry alterations shown here have been sufficiently replicated or demonstrated to be specific to the disease process of schizo-
phrenia to be considered established “facts;” solid arrows indicate abnormalities supported by convergent and/or replicated observations.  
Reproduced from ref 2: Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest.
2009;119:706-716. Copyright © American Society for Clinical Investigation 2009
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neurons impairs prefrontal network synchrony in
schizophrenia
Reduced GABA signaling from PV-containing GABA
neurons to the perisomatic region of pyramidal neurons
in the DLPFC might contribute to the pathophysiology
of working memory dysfunction via the following mech-
anisms. First, the activity of DLPFC GABA neurons is
essential for normal working memory function in mon-
keys.
71,72 Second, PV-positive GABA neurons and pyra-
midal neurons share common sources (eg, thalamic
afferents) of excitatory input.
55 The resulting feed-for-
ward, disynaptic inhibition creates a time window dur-
ing which the number of excitatory inputs required to
evoke pyramidal neuron firing must occur.
73Third, both
chandelier and basket neurons target multiple pyrami-
dal neurons,
74 enabling them to use this timing mecha-
nism to synchronize the activity of local populations of
pyramidal neurons.
75 Fourth, networks of PV-positive
GABA neurons, formed by both chemical and electrical
synapses, give rise to oscillatory activity in the gamma
band range, the synchronized firing of a neuronal popu-
lation at 30 to 80 Hz.
76,77 Interestingly, gamma band oscil-
lations in the human DLPFC increase in proportion to
working memory load,
78 and in subjects with schizo-
phrenia, prefrontal gamma band oscillations are reduced
bilaterally during a working memory task.
79 Thus, a
deficit in the synchronization of pyramidal cell firing,
resulting from impaired regulation of pyramidal cell net-
works by PV-positive GABA neurons, may contribute
to reduced levels of induced gamma band oscillations,
and consequently to impairments in cognitive tasks that
involve working memory in subjects with schizophre-
nia.
65 Interestingly, CCK/CB1R- and PV-containing cells
provide convergent sources of perisomatic inhibition to
pyramidal neurons that play specific roles in shaping net-
work activity, including complementary roles in regulat-
ing gamma band oscillations.
80Thus, alterations in CCK-
containing basket cells could also contribute to impaired
gamma oscillations in schizophrenia. 
The contribution of developmental plasticity to
GABA neuron alterations in schizophrenia
In the monkey prefrontal cortex DLPFC, the density of
symmetric, presumably GABA, synapses rises rapidly
during the third trimester of gestation and perinatal
period until stable, adult levels are achieved at 3 months
postnatal.
36 In contrast, pre- and postsynaptic markers of
the functional properties of chandelier axon inputs to
the axon initial segment (AIS) of pyramidal neurons
exhibit a very protracted maturation. Presynaptically,
immunoreactivities for the calcium-binding protein PV
and GAT1 in chandelier axon cartridges are not
detectable or low at birth, rise (albeit with different
developmental time courses) to peak levels early in post-
natal development that are sustained until ~15 months
of age, and then rapidly decline during adolescence until
stable adult levels are achieved.
34,81,82 Since chandelier
cartridges are readily visualized with Golgi staining
across postnatal development,
83 these changes in PV and
GAT1 immunoreactivity are likely to reflect shifts in the
concentration of these proteins rather than changes in
the presence of, or in the density of, axon terminals
within chandelier axon cartridges.
82 Postsynaptically,
GABAA receptors containing α2 subunits predominate
in pyramidal neuron AIS especially in cortical layers 2-
4.
84 The density of pyramidal neuron AIS immunoreac-
tive for α2 subunits is high at birth, then significantly
declines during adolescence before achieving stable
adult levels.
82These findings indicate that both pre- and
postsynaptic markers of GABA neurotransmission
undergo significant changes during postnatal develop-
ment, suggesting that the capacity to synchronize pyra-
midal neuron output in the prefrontal cortex (PFC)
might be in substantial flux until adulthood. 
The significance of these changes depends, at least in
part, on how GABA synapses are stabilized at the AIS
while the functional properties of GABA neurotrans-
mission at this location are changing during postnatal
development. For example, pyramidal neuron AIS con-
tain specific proteins that regulate synapse structure and
receptor clustering: i) Ankyrin-G, an adaptor molecule
that links various membrane proteins to the cytoskele-
ton, is localized to AIS,
85 and interactions between
ankyrin-G and the cell adhesion molecule, neurofascin,
are required for the formation and stabilization of
GABA synapses at AIS86; ii) βIV spectrin, which is
localized to the AIS of pyramidal neurons through its
direct interaction with ankryin-G,87 is a critical compo-
nent in the organization and stabilization of membrane
proteins at the AIS88; iii) The scaffolding protein
gephyrin facilitates the preferential accumulation of
gephyrin-GABAA receptor clusters, especially those
containing α2 subunits.
89 In monkey DLPFC, ankyrin-G-
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the first 6 months postnatal, but then remain stable,
whereas the density of gephyrin-labeled AIS is stable
through early postnatal development and then then
markedly declines during adolescence.
90Thus, molecular
determinants of the structural features that define
GABA inputs to pyramidal neuron AIS in monkey PFC
undergo distinct developmental trajectories, with differ-
ent types of changes occurring during the perinatal
period and adolescence (Figure 4). 
This complex and protracted postnatal maturation of the
inputs from PV-containing GABA neurons in the pri-
mate DLPFC provides a number of opportunities for
even subtle disturbances to have their effects amplified
as they alter the trajectories of the developmental events
that follow. For example, the marked developmental
changes in the axon terminals of PV-containing chande-
lier neurons, and their postsynaptic receptors, during the
perinatal period and adolescence, raises the possibility
that the alterations in schizophrenia of these markers
reflect a disturbance in these patterns of development.
These temporal correlations may explain how a range of
environmental factors (eg, labor-delivery complications,
urban place of rearing, and marijuana use during ado-
lescence) are all associated with increased risk for the
appearance of schizophrenia later in life. Although spec-
ulative, the current literature raises the possibility that
the GABA-related disturbances in schizophrenia repre-
sent an arrest of normal developmental trajectories. For
example, recent studies indicate that mRNA expression
for the α1 subunit of the GABAA receptor in the
DLPFC increases across postnatal development,
whereas the expression of the α2 subunit declines.
91Thus,
the elevated α2 subunit expression
60 and the decreased
α1 mRNA levels
92 in schizophrenia might reflect a devel-
opmental dysregulation of GABAA receptor α subunit
expression, where the changes in subunit expression with
age fail to undergo their full course. Under this scenario,
the alterations of DLPFC circuitry in schizophrenia may
render it unable to support higher levels of working
memory load, rendering the impaired performance in
schizophrenia analogous to the immature levels of work-
ing memory function seen in children.
93,94
Neuroplastic responses as targets 
for treatment
The findings reviewed above indicate that working
memory and related cognitive impairments in schizo-
phrenia are likely the result of a complex set of alter-
ations in prefrontal excitatory and inhibitory circuitry.
Some of these alterations appear to be deleterious
causes or consequences of disturbances in the functional
architecture of the DLPFC and interconnected brain
regions, whereas others may be best explained as com-
pensatory responses. In each case, they reflect the mor-
phological and molecular neuroplasticity of DLPFC cir-
cuitry in a disease state. Understanding whether the
disease-related change in a given molecule is a conse-
quence or compensation in the disease process has
important implications both for the nature of activity of
the drugs designed against that target and for the poten-
tial therapeutic value of the target. For example, is the
neuroplastic capacity of cortical circuitry sufficiently lim-
ited that pharmacological augmentation of a compen-
satory response is feasible? The results of a recent proof-
of-concept clinical trial suggest that this may be the case.
For example, the idea that GABAA receptors contain-
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Figure 4. Schematic summary of the trajectories of pyramidal neuron
axon initial segments and chandelier neuron axon cartridges
labeled with different markers across postnatal development
in area 46 of monkey PFC. Lines for each marker represent
the percent maximal value achieved plotted against age in
months after birth on a log scale. Arrowheads demarcate the
indicated ages in months, and the white area indicates the
approximate age range corresponding to adolescence in this
species. GAT1 indicates GABA membrane transporter 1; PV
indicates parvalbumin.   
Reproduced from ref 90: Cruz DA, Lovallo EM, Stockton S, Rasband M,
Lewis DA. Postnatal development of synaptic structure proteins in pyra-
midal neuron axon initial segments in monkey prefrontal cortex. J Comp
Neurol. 2009;514:353-367. Copyright © Wiley-Liss 2009
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Neuroplasticidad de los circuitos corticales
excitatorios e inhibitorios en la 
esquizofrenia
La esquizofrenia es un trastorno del neurodesarro-
llo que se caracteriza por déficit en los procesos
cognitivos, los que están mediados por los circuitos
de la corteza prefrontal dorsolateral (CPFDL). Estos
déficit están asociados con una amplia gama de
alteraciones en los circuitos de la CPFDL; algunos de
ellos reflejan la patología de la enfermedad y otros
cómo la neuroplasticidad cerebral responde al pro-
ceso patológico subyacente. En este artículo se revi-
san las alteraciones en los componentes excitatorios
e inhibitorios de los circuitos de la CPFDL desde la
perspectiva de la neuroplasticidad del desarrollo y
se discuten sus implicancias en la identificación de
nuevas terapias. 
Neuroplasticité des circuits corticaux 
excitateurs et inhibiteurs dans la 
schizophrénie
La schizophrénie est une maladie d’origine neuro-
développementale caractérisée par un déficit des
processus cognitifs transmis par les circuits du cor-
tex dorsolatéral préfrontal (CPFDL). Ces déficits s’as-
socient à un ensemble d’altérations des circuits du
CPFDL, dont certains reflètent la physiopathologie
du trouble et dont d’autres sont la conséquence de
la neuroplasticité cérébrale en réponse au proces-
sus pathologique sous-jacent. Cet article propose
une revue des troubles des composants excitateurs
et inhibiteurs des circuits du CPFDL selon une pers-
pective de  neuroplasticité  développementale, et
traite de leurs implications pour l’identification de
nouvelles cibles thérapeutiques.
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